{"id":4741,"date":"2023-06-13T13:19:17","date_gmt":"2023-06-13T11:19:17","guid":{"rendered":"https:\/\/www.ptc.cz\/moderni-diagnostika\/pet-ct\/informace-o-vysetreni-pet-ct-pro-lekare\/"},"modified":"2024-06-21T13:53:59","modified_gmt":"2024-06-21T11:53:59","slug":"informacije-o-pet-ct-pregledu-za-lijecnike","status":"publish","type":"page","link":"https:\/\/www.ptc.cz\/hr\/moderna-dijagnostika\/pet-ct\/informacije-o-pet-ct-pregledu-za-lijecnike\/","title":{"rendered":"Informacije o&nbsp;PET\/CT pregledu za lije\u010dnike"},"content":{"rendered":"<div class=\"row\">\n<div class=\"col js-imageOptimalization\">\n<p>Protonov\u00e9 centrum v&nbsp;Praze nab\u00edz\u00ed\u00a0<strong>vybran\u00e1 diagnostick\u00e1 vy\u0161et\u0159en\u00ed,<\/strong>\u00a0a to magnetickou rezonanci (MR) a&nbsp;pozitronovou emisn\u00ed tomografii v&nbsp;kombinaci s&nbsp;po\u010d\u00edta\u010dovou tomografi\u00ed (PET\/CT). Vy\u0161et\u0159en\u00ed prov\u00e1d\u00edme nejen u&nbsp;onkologicky nemocn\u00fdch pacient\u016f Protonov\u00e9ho centra, ale i&nbsp;u&nbsp;v\u0161ech ostatn\u00edch pacient\u016f, kter\u00fdm o\u0161et\u0159uj\u00edc\u00ed l\u00e9ka\u0159 vystav\u00ed \u017e\u00e1danku.<\/p>\n<h4>Odd\u011blen\u00ed Nukle\u00e1rn\u00ed medic\u00edny prov\u00e1d\u00ed n\u00e1sleduj\u00edc\u00ed vy\u0161et\u0159en\u00ed:<\/h4>\n<ul>\n<li>PET\/CT trupu s&nbsp;vyu\u017eit\u00edm radiofarmaka fluorodeoxygluk\u00f3zy (FDG),<\/li>\n<li>PET\/CT trupu s&nbsp;vyu\u017eit\u00edm radiofarmaka fluorocholinu (FCh),<\/li>\n<li>PET\/CT trupu s&nbsp;vyu\u017eit\u00edm radioafarmaka 18F-fluciclovinu (Axumin),<\/li>\n<li>PET\/CT mozku s&nbsp;vyu\u017eit\u00edm radiofarmaka fluorodeoxygluk\u00f3zy (FDG),<\/li>\n<li>PET\/CT pro pl\u00e1nov\u00e1n\u00ed radioterapie.<\/li>\n<\/ul>\n<h4>Term\u00edny objedn\u00e1n\u00ed jsou kr\u00e1tk\u00e9, jedn\u00e1 se o&nbsp;rozmez\u00ed 3 &#8211; 4 t\u00fddn\u016f. Ochotn\u011b v\u00e1m zavol\u00e1me, pokud se uvoln\u00ed d\u0159\u00edv\u011bj\u0161\u00ed term\u00edn.<\/h4>\n<p>&nbsp;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"is-loaded\" src=\"https:\/\/www.ptc.cz\/uploads\/thumbs\/medium-150-dpi-mi-biograph-vision-closeup-image-18-1200x1200.jpg\" alt=\"medium-150-dpi-mi-biograph-vision-closeup-image-18.jpg (581 KB)\" width=\"619\" height=\"464\" data-src=\"\/uploads\/thumbs\/medium-150-dpi-mi-biograph-vision-closeup-image-18-1200x1200.jpg\" \/><\/p>\n<h3><\/h3>\n<h4>1. Jak\u00a0objednat pacienta na&nbsp;PET\/CT vy\u0161et\u0159en\u00ed<\/h4>\n<p><strong>Na vy\u0161et\u0159en\u00ed PET\/CT<\/strong>, tedy vy\u0161et\u0159en\u00ed pozitronovou emisn\u00ed tomografi\u00ed v&nbsp;kombinaci s&nbsp;po\u010d\u00edta\u010dovou tomografi\u00ed, <strong>objedn\u00e1te pacienty na&nbsp;telefonn\u00edm \u010d\u00edsle\u00a0+420&nbsp;222&nbsp;999&nbsp;046.<\/strong>\u00a0<strong>N\u00e1sledn\u011b za\u0161lete vypln\u011bnou \u017e\u00e1danku na&nbsp;e-mail<\/strong>:\u00a0<strong>zadanky@ptc.cz<\/strong>. Rezervov\u00e1n\u00ed term\u00ednu a&nbsp;zasl\u00e1n\u00ed \u017e\u00e1danky p\u0159edem zjednodu\u0161\u00ed a&nbsp;zrychl\u00ed syst\u00e9m objedn\u00e1n\u00ed.<\/p>\n<p>Jsme schopni zajistit tak\u00e9 kvalitn\u00ed vy\u0161et\u0159en\u00ed v&nbsp;celkov\u00e9 anestezii \u010di analgosedaci u&nbsp;d\u011btsk\u00fdch pacient\u016f i&nbsp;dosp\u011bl\u00fdch pacient\u016f se specifick\u00fdmi probl\u00e9my (klaustrofobie).<\/p>\n<h5><\/h5>\n<h4><strong>2. PET\/CT &#8211; ke sta\u017een\u00ed pro l\u00e9ka\u0159e zde:\u00a0<\/strong><\/h4>\n<ul>\n<li><a href=\"https:\/\/www.ptc.cz\/wp-content\/uploads\/2023\/08\/brozura-a5-pet-ct-nahled-v2.pdf\"><strong><em>Pou\u010den\u00ed pro pacienta PET\/CT vy\u0161et\u0159en\u00ed (PDF ke sta\u017een\u00ed)<\/em><\/strong><\/a><\/li>\n<\/ul>\n<p>Abychom va\u0161eho pacienta u\u0161et\u0159ili p\u0159\u00edpadn\u00fdch obav z&nbsp;vy\u0161et\u0159en\u00ed, p\u0159ipravili jsme po n\u011bj z\u00e1kladn\u00ed informace o&nbsp;PET\/CT vy\u0161et\u0159en\u00ed.<\/p>\n<ul>\n<li><a href=\"https:\/\/www.ptc.cz\/wp-content\/uploads\/2023\/08\/informovany-souhlas-petct-vysetreni-cs-verze-5-doc.docx\">Informovan\u00fd souhlas pacienta s\u00a0PET\/CT vy\u0161et\u0159en\u00edm (ke sta\u017een\u00ed)<\/a><\/li>\n<\/ul>\n<p>Informovan\u00fd souhlas s&nbsp;PET\/CT vy\u0161et\u0159en\u00edm si m\u016f\u017ee pacient prostudovat v&nbsp;klidu domova. M\u016f\u017ee jej vyplnit a&nbsp;podepsat a\u017e p\u0159i n\u00e1v\u0161t\u011bv\u011b Protonov\u00e9ho centra.<\/p>\n<p>&nbsp;<\/p>\n<h4><strong>3. Co je PET\/CT<\/strong><\/h4>\n<p><strong>PET\/CT je diagnostick\u00e1 zobrazovac\u00ed metoda nukle\u00e1rn\u00ed medic\u00edny<\/strong>. Metoda se pou\u017e\u00edv\u00e1 zejm\u00e9na k&nbsp;diagnostice n\u00e1dorov\u00fdch onemocn\u011bn\u00ed, p\u0159\u00edpadn\u011b z\u00e1n\u011bt\u016f, p\u0159i\u010dem\u017e vyu\u017e\u00edv\u00e1 f\u00fazi neboli kombinaci funk\u010dn\u00edho (metabolick\u00e9ho) a&nbsp;anatomick\u00e9ho (morfologick\u00e9ho) obrazu.<\/p>\n<p>PET\/CT vy\u0161et\u0159en\u00ed pat\u0159\u00ed v&nbsp;r\u00e1mci zobrazovac\u00edch metod k&nbsp;nejmodern\u011bj\u0161\u00edm. Kombinuje v\u00fdhody metabolick\u00e9ho vy\u0161et\u0159en\u00ed (PET) a&nbsp;struktur\u00e1ln\u00edho zobrazen\u00ed (CT). Jedn\u00e1 se o&nbsp;tzv. hybridn\u00ed zobrazen\u00ed. D\u00edky tomu umo\u017e\u0148uje ur\u010dit p\u0159esnou anatomickou lokalizaci patologick\u00e9ho n\u00e1lezu a&nbsp;z\u00e1rove\u0148 objasnit nejasn\u00e9 struktur\u00e1ln\u00ed zm\u011bny. T\u00edm se v\u00fdznamn\u011b zvy\u0161uje v\u00fdt\u011b\u017enost obou metod. Proveden\u00ed obou vy\u0161et\u0159en\u00ed sou\u010dasn\u011b zjednodu\u0161uje mnohdy zdlouhav\u00fd, pro pacienty n\u00e1ro\u010dn\u00fd proces.<\/p>\n<ul>\n<li><strong>Nej\u010dast\u011bji vyu\u017e\u00edvan\u00e1 metoda v&nbsp;onkologii<\/strong>\u00a0\u2013 u&nbsp;pacient\u016f s&nbsp;podez\u0159en\u00edm na&nbsp;n\u00e1dorov\u00e9 onemocn\u011bn\u00ed nebo s&nbsp;ji\u017e potvrzen\u00fdm n\u00e1dorov\u00fdm onemocn\u011bn\u00edm. V&nbsp;tomto p\u0159\u00edpad\u011b se vy\u0161et\u0159en\u00ed prov\u00e1d\u00ed p\u0159ed zah\u00e1jen\u00edm l\u00e9\u010dby (na&nbsp;z\u00e1klad\u011b tohoto vy\u0161et\u0159en\u00ed doch\u00e1z\u00ed ke zm\u011bn\u011b l\u00e9\u010debn\u00e9ho postupu a\u017e ve 25&nbsp;% p\u0159\u00edpad\u016f).<\/li>\n<li>Vy\u0161et\u0159en\u00ed se ale tak\u00e9 \u010dasto prov\u00e1d\u00ed jako\u00a0<strong>kontrola po proveden\u00e9 l\u00e9\u010db\u011b<\/strong>\u00a0(zhodnocen\u00ed efektu l\u00e9\u010dby a&nbsp;pro jej\u00ed p\u0159\u00edpadnou \u00fapravu) nebo pro pl\u00e1nov\u00e1n\u00ed radioterapie.<\/li>\n<li>PET\/CT se rovn\u011b\u017e uplat\u0148uje v&nbsp;diagnostice z\u00e1n\u011btliv\u00fdch, resp. autoimunitn\u00edch onemocn\u011bn\u00ed, v&nbsp;neurologii a&nbsp;v&nbsp;kardiologii.<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><strong>Na\u0161e pracovi\u0161t\u011b je vybaveno p\u0159\u00edstrojem: PET\/CT Siemens Biograph Vision 450<\/strong><\/p>\n<p>Hybridn\u00ed p\u0159\u00edstroj pro vy\u0161et\u0159en\u00ed PET\/CT, tedy pozitronovou emisn\u00ed tomografii v&nbsp;kombinaci s&nbsp;v\u00fdpo\u010detn\u00ed tomografi\u00ed, kombinuje v\u00fdhody metabolick\u00e9ho vy\u0161et\u0159en\u00ed (PET) a&nbsp;struktur\u00e1ln\u00edho zobrazen\u00ed (CT). Jeho pom\u011brn\u011b kr\u00e1tk\u00e9 a&nbsp;nadstandardn\u011b \u0161irok\u00e9 gantry, neboli ,,tunel\u201c, o&nbsp;pr\u016fm\u011bru 78 cm a&nbsp;vy\u0161et\u0159ovac\u00ed st\u016fl s&nbsp;nosnost\u00ed a\u017e 227&nbsp;kg umo\u017e\u0148uj\u00ed nejen vy\u0161et\u0159en\u00ed pacient\u016f statn\u00e9 postavy a&nbsp;pacient\u016f citliv\u00fdch na&nbsp;st\u00edsn\u011bn\u00e9 prostory, ale i&nbsp;vy\u0161et\u0159en\u00ed s&nbsp;pom\u016fckami pro pl\u00e1nov\u00e1n\u00ed radioterapie. D\u00edky vysok\u00e9 efektivit\u011b sn\u00edm\u00e1n\u00ed umo\u017e\u0148uje sn\u00ed\u017eit aplikovanou aktivitu radiofarmaka, a&nbsp;tedy ve v\u00fdsledku i&nbsp;mo\u017enost sn\u00ed\u017een\u00ed radia\u010dn\u00ed z\u00e1t\u011b\u017ee pacient\u016f.\u00a0 P\u0159\u00edstroj je t\u00e9\u017e vybaven algoritmem pro potla\u010den\u00ed metalick\u00fdch artefakt\u016f, nap\u0159. v&nbsp;okol\u00ed kloubn\u00edch n\u00e1hrad.<\/p>\n<p>&nbsp;<\/p>\n<h4>4. Pou\u017eit\u00ed radiofarmak<\/h4>\n<p>Ke zhotoven\u00ed metabolick\u00e9ho obrazu je zapot\u0159eb\u00ed nitro\u017eiln\u00ed aplikace speci\u00e1ln\u00edch radioaktivn\u00edch l\u00e1tek, naz\u00fdvan\u00fdch <strong>radiofarmaka,<\/strong>\u00a0(nej\u010dast\u011bji F-fluordeoxygluk\u00f3za (FDG) a&nbsp;F-chol\u00edn (FCH)). Aplikovan\u00e9 radioaktivn\u00ed l\u00e1tky se z&nbsp;t\u011bla pacienta rychle vylu\u010duj\u00ed mo\u010d\u00ed, nep\u016fsob\u00ed alergie ani\u00a0<strong>neomezuj\u00ed \u0159\u00edzen\u00ed motorov\u00fdch vozide<\/strong>l.<\/p>\n<h4><span data-contrast=\"auto\">18F-FDG (Fluorodeoxygluk\u00f3za) <\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/h4>\n<p><span data-contrast=\"auto\">FDG je analog gluk\u00f3zy, kter\u00fd m\u00e1 tendenci se hromadit v&nbsp;tk\u00e1n\u00edch s&nbsp;vysokou pot\u0159ebou gluk\u00f3zy, jako jsou n\u00e1dory a&nbsp;z\u00e1n\u011btliv\u00e9 bu\u0148ky.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><strong>Indikacemi k&nbsp;vy\u0161et\u0159en\u00ed jsou: \u00a0<\/strong><\/p>\n<p><span data-contrast=\"auto\">Diferenci\u00e1ln\u00ed diagnostika benign\u00edch a&nbsp;malign\u00edch lo\u017eiskov\u00fdch l\u00e9z\u00ed, p\u00e1tr\u00e1n\u00ed po nezn\u00e1m\u00e9m prim\u00e1rn\u00edm malign\u00edm lo\u017eisku, stanoven\u00ed rozsahu onkologick\u00e9ho onemocn\u011bn\u00ed, monitorov\u00e1n\u00ed efektu terapie, diagnostika recidivy n\u00e1dorov\u00e9ho onemocn\u011bn\u00ed, pl\u00e1nov\u00e1n\u00ed rozsahu radioterapie, detekce z\u00e1n\u011btliv\u00e9ho lo\u017eiska.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">\u00a0<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<h4><span data-contrast=\"auto\">18F-FMISO (Fluoromisonidazole)<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/h4>\n<p><span data-contrast=\"auto\">18F-FMISO slou\u017e\u00ed jednak k&nbsp;pr\u016fkazu ischemie v&nbsp;n\u00e1doru, co\u017e m\u00e1 v\u00fdznam zejm\u00e9na pro zp\u016fsob l\u00e9\u010dby, ale pou\u017e\u00edv\u00e1 se tak\u00e9 k&nbsp;odhadu progn\u00f3zy onemocn\u011bn\u00ed.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><strong>Mezi hlavn\u00ed indikace v&nbsp;sou\u010dasn\u00e9 dob\u011b pat\u0159\u00ed: \u00a0<\/strong><\/p>\n<ul>\n<li><span data-contrast=\"auto\">N\u00e1dory mozku (gliomy) <\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<li><span data-contrast=\"auto\">N\u00e1dory v&nbsp;oblasti hlavy a&nbsp;krku (zejm\u00e9na dla\u017edicobun\u011b\u010dn\u00e9 karcinomy) <\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<li><span data-contrast=\"auto\">Nemalobun\u011b\u010dn\u00fd plicn\u00ed karcinom (NSCLC) <\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<li><span data-contrast=\"auto\">Karcinom ledviny <\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<li><span data-contrast=\"auto\">Karcinom prsu <\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<li><span data-contrast=\"auto\">Sarkom <\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><span data-contrast=\"auto\">\u00a0<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<h4><span data-contrast=\"auto\">18F-FCH (Fluorocholin)<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/h4>\n<p><strong>Indikacemi k&nbsp;vy\u0161et\u0159en\u00ed jsou: \u00a0<\/strong><\/p>\n<p><span data-contrast=\"auto\">Karcinom prostaty, lokalizace adenomu \u010di hyperplazie p\u0159\u00ed\u0161t\u00edtn\u00fdch t\u011bl\u00edsek p\u0159i podez\u0159en\u00ed na&nbsp;prim\u00e1rn\u00ed hyperparatyre\u00f3zu.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">\u00a0<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<h4><span data-contrast=\"auto\">18F-FCV (Fluciclovine\/Axumin)<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/h4>\n<p><span data-contrast=\"auto\"><strong>Indikacemi k&nbsp;vy\u0161et\u0159en\u00ed jsou:<\/strong> Detekce recidivy karcinomu prostaty.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<h4><span data-contrast=\"auto\">68GA-PSMA (Prostate specific membrane antigen)<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/h4>\n<p><strong>Indikace k\u00a0vy\u0161et\u0159en\u00ed jsou:\u00a0<\/strong><\/p>\n<p><span data-contrast=\"auto\">Lokalizace karcinomu prostaty.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">\u00a0<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<h4><span data-contrast=\"auto\">18F-FES (Fluoroestradiolum)<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/h4>\n<p><span data-contrast=\"auto\">Vy\u0161et\u0159en\u00ed pomoc\u00ed 18F-FES\/PET je mo\u017eno prov\u00e9st u&nbsp;karcinomu prsu: <\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<ul>\n<li><span data-contrast=\"auto\">pro staging a&nbsp;restaging ER pozitivn\u00edho karcinomu prsu, <\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<li><span data-contrast=\"auto\">k predikci odpov\u011bdi pacienta na&nbsp;endokrinn\u00ed l\u00e9\u010dbu, <\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<li><span data-contrast=\"auto\">ke stanoven\u00ed heterogenity exprese estrogenov\u00fdch receptor\u016f u&nbsp;prim\u00e1rn\u00edho n\u00e1doru a&nbsp;jeho metast\u00e1z. <\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/li>\n<\/ul>\n<p><span data-contrast=\"auto\">\u00a0<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p><span data-contrast=\"auto\">Indikace vy\u0161et\u0159en\u00ed mus\u00ed b\u00fdt schv\u00e1lena multidisciplin\u00e1rn\u00edm t\u00fdmem zam\u011b\u0159en\u00fdm na&nbsp;karcinom prsu v&nbsp;r\u00e1mci Komplexn\u00edho onkologick\u00e9ho centra. Je nutn\u00e9 zohlednit eventu\u00e1ln\u00ed nutnost vysazen\u00ed antiestrogenn\u00ed l\u00e9\u010dby.<\/span><span data-ccp-props=\"{&quot;201341983&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:259}\">\u00a0<\/span><\/p>\n<p>Morfologick\u00fd obraz z\u00edsk\u00e1v\u00e1me pomoc\u00ed plnohodnotn\u00e9ho CT vy\u0161et\u0159en\u00ed s&nbsp;aplikac\u00ed jodov\u00e9ho kontrastu (pokud nen\u00ed kontraindikov\u00e1n). Vy\u0161et\u0159en\u00ed je \u010dasov\u011b n\u00e1ro\u010dn\u00e9,\u00a0<strong>jedn\u00e1 se p\u0159ibli\u017en\u011b o&nbsp;3 hodiny,<\/strong>\u00a0proto\u017ee se standardn\u011b sn\u00edm\u00e1 velk\u00fd rozsah t\u011bla (naz\u00fdv\u00e1no celot\u011blov\u00e9 vy\u0161et\u0159en\u00ed).<\/p>\n<p>&nbsp;<\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Protonov\u00e9 centrum v&nbsp;Praze nab\u00edz\u00ed\u00a0vybran\u00e1 diagnostick\u00e1 vy\u0161et\u0159en\u00ed,\u00a0a to magnetickou rezonanci (MR) a&nbsp;pozitronovou emisn\u00ed tomografii v&nbsp;kombinaci s&nbsp;po\u010d\u00edta\u010dovou tomografi\u00ed (PET\/CT). Vy\u0161et\u0159en\u00ed prov\u00e1d\u00edme nejen u&nbsp;onkologicky nemocn\u00fdch pacient\u016f Protonov\u00e9ho centra, ale i&nbsp;u&nbsp;v\u0161ech ostatn\u00edch pacient\u016f, kter\u00fdm o\u0161et\u0159uj\u00edc\u00ed l\u00e9ka\u0159 vystav\u00ed \u017e\u00e1danku. Odd\u011blen\u00ed Nukle\u00e1rn\u00ed medic\u00edny prov\u00e1d\u00ed n\u00e1sleduj\u00edc\u00ed vy\u0161et\u0159en\u00ed: PET\/CT trupu s&nbsp;vyu\u017eit\u00edm radiofarmaka fluorodeoxygluk\u00f3zy (FDG), PET\/CT trupu s&nbsp;vyu\u017eit\u00edm radiofarmaka fluorocholinu (FCh), PET\/CT trupu s&nbsp;vyu\u017eit\u00edm&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4729,"parent":4734,"menu_order":114,"comment_status":"closed","ping_status":"closed","template":"template-page-with-sidebar.php","meta":{"footnotes":""},"class_list":["post-4741","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.ptc.cz\/hr\/wp-json\/wp\/v2\/pages\/4741","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ptc.cz\/hr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ptc.cz\/hr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ptc.cz\/hr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ptc.cz\/hr\/wp-json\/wp\/v2\/comments?post=4741"}],"version-history":[{"count":2,"href":"https:\/\/www.ptc.cz\/hr\/wp-json\/wp\/v2\/pages\/4741\/revisions"}],"predecessor-version":[{"id":4772,"href":"https:\/\/www.ptc.cz\/hr\/wp-json\/wp\/v2\/pages\/4741\/revisions\/4772"}],"up":[{"embeddable":true,"href":"https:\/\/www.ptc.cz\/hr\/wp-json\/wp\/v2\/pages\/4734"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ptc.cz\/hr\/wp-json\/wp\/v2\/media\/4729"}],"wp:attachment":[{"href":"https:\/\/www.ptc.cz\/hr\/wp-json\/wp\/v2\/media?parent=4741"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}